Rheos Feasibility Trial
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Implantation of the Rheos System
Standard of care medical management
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension
Eligibility Criteria
Inclusion Criteria:
- Be at least 21 years of age.
- Have been assessed to have bilateral carotid bifurcations located at or below C3-C4.
- Have an office cuff systolic blood pressure greater than or equal to 160 mmHg and a 24-hour ambulatory systolic blood pressure greater than or equal to 150 mmHg despite at least one month of full therapy with at least three (3) anti-hypertensive medications, of which at least one (1) must be a diuretic.
- Must be certified by the investigator hypertension specialist as compliant with taking full doses of medication.
- Have signed a CVRx approved informed consent for participation in this study.
Exclusion Criteria:
Have been diagnosed with:
- Baroreflex failure
- Cardiac bradyarrhythmias
- Chronic atrial fibrillation
- Had a heart transplant
- Have carotid atherosclerosis producing a 50% or greater reduction in linear diameter as determined by ultrasound or angiographic evaluation as determined within six months of enrollment in the trial.
- Have Grade C ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation.
- Have prior surgery or radiation in either carotid sinus region.
- Currently have implanted electrical medical devices such as cardiac pacing, defibrillation or neurologic stimulation systems.
- Are pregnant or contemplating pregnancy during the 13-month follow-up period.
- Currently undergoing dialysis.
- Have hypertension secondary to a treatable cause.
- Have clinically significant cardiac valvular disease.
- Are unable or unwilling to fulfill the protocol medication compliance and follow-up requirements.
- Are unlikely to survive the protocol follow-up period.
Are enrolled in another concurrent clinical trial.
-
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Rheos Device
Medical Management
Arm Description
Outcomes
Primary Outcome Measures
Rheos Feasibility Study
To summarize the efficacy of the Rheos System by estimating the reduction of systolic blood pressure associated with activation of the Rheos System at 4 and 13 months post implant when compared to baseline (1-month post implant).
To describe the safety of the Rheos System by summarizing all system related adverse events and estimating the serious sytem related event-free rate through 4 and 13 months post-implant.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01077180
Brief Title
Rheos Feasibility Trial
Official Title
Rheos Feasibility Trial- A Study of Baroreflex Hypertension TherapyTM in Refractory Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
January 2005 (undefined)
Primary Completion Date
December 2007 (Actual)
Study Completion Date
October 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
CVRx, Inc.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The Rheos Feasibility Trial is designed to assess safety, device performance, and protocol parameters of the CVRx Rheos Baroreflex Therapy in patients with severe hypertension that are refractory to full drug therapy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
16 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Rheos Device
Arm Type
Experimental
Arm Title
Medical Management
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Implantation of the Rheos System
Intervention Description
Open label
Intervention Type
Other
Intervention Name(s)
Standard of care medical management
Intervention Description
Patients will continue with medical therapy for standard of care of their hypertension.
Primary Outcome Measure Information:
Title
Rheos Feasibility Study
Description
To summarize the efficacy of the Rheos System by estimating the reduction of systolic blood pressure associated with activation of the Rheos System at 4 and 13 months post implant when compared to baseline (1-month post implant).
To describe the safety of the Rheos System by summarizing all system related adverse events and estimating the serious sytem related event-free rate through 4 and 13 months post-implant.
Time Frame
13 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Be at least 21 years of age.
Have been assessed to have bilateral carotid bifurcations located at or below C3-C4.
Have an office cuff systolic blood pressure greater than or equal to 160 mmHg and a 24-hour ambulatory systolic blood pressure greater than or equal to 150 mmHg despite at least one month of full therapy with at least three (3) anti-hypertensive medications, of which at least one (1) must be a diuretic.
Must be certified by the investigator hypertension specialist as compliant with taking full doses of medication.
Have signed a CVRx approved informed consent for participation in this study.
Exclusion Criteria:
Have been diagnosed with:
Baroreflex failure
Cardiac bradyarrhythmias
Chronic atrial fibrillation
Had a heart transplant
Have carotid atherosclerosis producing a 50% or greater reduction in linear diameter as determined by ultrasound or angiographic evaluation as determined within six months of enrollment in the trial.
Have Grade C ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation.
Have prior surgery or radiation in either carotid sinus region.
Currently have implanted electrical medical devices such as cardiac pacing, defibrillation or neurologic stimulation systems.
Are pregnant or contemplating pregnancy during the 13-month follow-up period.
Currently undergoing dialysis.
Have hypertension secondary to a treatable cause.
Have clinically significant cardiac valvular disease.
Are unable or unwilling to fulfill the protocol medication compliance and follow-up requirements.
Are unlikely to survive the protocol follow-up period.
Are enrolled in another concurrent clinical trial.
-
12. IPD Sharing Statement
Learn more about this trial
Rheos Feasibility Trial
We'll reach out to this number within 24 hrs